- Home
- CDRE vs ELVN Comparison
CDRE vs ELVN Comparison
Compare CDRE & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDRE
- ELVN
- Stock Information
- Founded
- CDRE 2012
- ELVN 2016
- Country
- CDRE United States
- ELVN United States
- Employees
- CDRE N/A
- ELVN N/A
- Industry
- CDRE Industrial Specialties
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- CDRE Health Care
- ELVN Health Care
- Exchange
- CDRE Nasdaq
- ELVN Nasdaq
- Market Cap
- CDRE 1.3B
- ELVN 1.2B
- IPO Year
- CDRE 2021
- ELVN 2020
- Fundamental
- Price
- CDRE $32.76
- ELVN $18.50
- Analyst Decision
- CDRE Buy
- ELVN Strong Buy
- Analyst Count
- CDRE 2
- ELVN 5
- Target Price
- CDRE $31.50
- ELVN $41.20
- AVG Volume (30 Days)
- CDRE 212.8K
- ELVN 459.4K
- Earning Date
- CDRE 11-05-2025
- ELVN 11-12-2025
- Dividend Yield
- CDRE 1.16%
- ELVN N/A
- EPS Growth
- CDRE N/A
- ELVN N/A
- EPS
- CDRE 0.93
- ELVN N/A
- Revenue
- CDRE $572,607,000.00
- ELVN N/A
- Revenue This Year
- CDRE $12.55
- ELVN N/A
- Revenue Next Year
- CDRE $7.70
- ELVN $25.00
- P/E Ratio
- CDRE $35.16
- ELVN N/A
- Revenue Growth
- CDRE 7.66
- ELVN N/A
- 52 Week Low
- CDRE $27.07
- ELVN $13.30
- 52 Week High
- CDRE $40.28
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- CDRE 59.71
- ELVN 39.08
- Support Level
- CDRE $30.89
- ELVN $18.80
- Resistance Level
- CDRE $32.58
- ELVN $21.30
- Average True Range (ATR)
- CDRE 0.84
- ELVN 1.08
- MACD
- CDRE 0.28
- ELVN -0.13
- Stochastic Oscillator
- CDRE 97.16
- ELVN 12.23
About CDRE Cadre Holdings Inc.
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.